<DOC>
	<DOCNO>NCT01282177</DOCNO>
	<brief_summary>The overall objective study provide ongoing assessment safety effectiveness seasonal pandemic H1N1 vaccine prevention ILI ( influenza like illness ) , ILI-associated work absenteeism , laboratory-confirmed influenza cohort Canadian HCP ( Health care provider ) . Given uncertainty around time provision seasonal influenza immunization HCP 2009/10 influenza season , study focus evaluation safety effectiveness pandemic influenza immunization Year 1 evaluation recommend influenza vaccine Years 2 3 .</brief_summary>
	<brief_title>Influenza Vaccine Safety Effectiveness Healthcare Providers</brief_title>
	<detailed_description>Participants Year 1 ( 2009/10 ) recruit begin Oct. 1 end pandemic H1N1 influenza immunization campaign . Participants follow day vaccination end influenza season approximately Oct-April season . At initial visit , participant 1 tube blood ( 10cc ) collect time enrolment determine baseline antibody titres pandemic H1N1 influenza strain past current year 's seasonal influenza vaccine . Participants receive automate email reminder link follow-up web-based questionnaire weekly interval follow completion baseline survey end influenza season . If participant report respiratory illness , receive follow-up questionnaire ask detail illness include occurrence respiratory illness associate symptom , contact patient household member respiratory illness , respiratory symptom-related healthcare utilization , prescription over-the-counter product use treatment respiratory illness , number day work miss due respiratory illness work symptomatic respiratory tract infection . An email sent participant every Monday morning season remind participant complete weekly diary report send nasal swab symptom acute respiratory illness . At initial visit participant teach collect nasal swab practice swab presence study nurse/research associate . Participants instruct collect nasal swab return swab soon possible onset ILI respiratory illness ( target &lt; 48h onset ) . Participants ask collect swab develop symptom compatible viral respiratory tract infection ( fever without apparent source OR new symptom least 2 follow -cough , runny/stuffy nose , sneeze , sore/scratchy throat , hoarseness , malaise , myalgia , headache , fatigue OR one local symptom ( runny/stuffy nose , sneeze , sore/scratchy throat , hoarseness , cough ) plus one systemic symptom ( fever , malaise , myalgia , headache , fatigue ) . If prefer , nasopharyngeal swab collect member study team soon possible onset symptom .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 ) 1869 year old , inclusive , Sept. 1 year enrolment ; 2 ) understand study , agree provision , give write informed consent participate ; 3 ) available followup least 1 influenza season 4 ) convenient access computer internet access basic skill use internet ; 5 ) employ fullor part time ( &gt; 8 hours/week ) acute care hospital ( occupation ) , physician midwife , work least 8 hour per week acute care hospital . 1. plan spend two consecutive week outside Canada winter study period ( Oct. 15 Apr . 15 ) ; 2. receive immunoglobulin within 6 month study entry ; 3. planning take leave work two consecutive week winter study period ( e.g . maternity medical leave ) ; 4. participate trial would result receipt investigational medication study period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>surveillance , safety , tolerability , vaccine</keyword>
</DOC>